App-Quantinova.ai

Disease recurrence patterns in patients undergoing bowel resections for Crohn’s disease.

Ahmed, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

Allegretti, J.R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tasocitinib

Pre-screening IBD patients starting biologic therapies, a positive single centre quality improvement project

Colclough, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan®

Raine, T - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Methylprednisolone

Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study.

Jenkinson, P - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.

Radford-Smith, D - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Infliximab

Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials

Peyrin-Biroulet, L - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess: The Leeds Steroids study

Rosiou, K - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease

Brownson, E - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

FA-8

Optimising response to infliximab in the management of perianal Crohn’s disease

SHAH , R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Infliximab

Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study

Karki, C - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Partial enteral nutrition use for Crohn’s disease management: a systematic review

Jatkowska, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenanc

Parkes, G - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

ABT-494

Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre study

Aleman Gonzalez, H - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Infliximab

Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study

Lim, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

Entyvio

Robotic surgery significantly improves outcomes for patients with inflammatory bowel disease

Karategos, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

A qualitative exploration of acceptability of long-term use of oral nutritional supplement drinks as partial enteral nutrition in adolescent and adult Crohn's Disease

Mu, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Safety analysis of tofacitinib in ulcerative colitis: Real-world outcomes from a three-year UK observational cohort study

Honap, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Tasocitinib

Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease

Derikx, L - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease

Hosack, T - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Filters

45280 Abstracts